We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+29.18%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$11.1B
AUM Growth
+$971M
Cap. Flow
-$906M
Cap. Flow %
-8.14%
Top 10 Hldgs %
79.46%
Holding
34
New
2
Increased
12
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$120M
2
UTHR icon
United Therapeutics
UTHR
+$83.2M
3
DFTX
Definium Therapeutics
DFTX
+$54.1M
4
COAG
Hemab Therapeutics
COAG
+$53.1M
5
ARWR icon
Arrowhead Research
ARWR
+$48.4M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$492M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$454M
3
TERN
Terns Pharmaceuticals
TERN
+$300M
4
SLNO
Soleno Therapeutics
SLNO
+$77M
5
ALKS icon
Alkermes
ALKS
+$42.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Avoro Capital Advisors held 34 positions worth $11.1B, up 9.6% from $10.2B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Avoro Capital Advisors withdrew a net $906M in Q2 2026, closing 8 positions and reducing 3 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $492M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Hemab Therapeutics worth $70.7M.

  • Avoro Capital Advisors's largest Q2 2026 buy was Hemab Therapeutics: 1,925,150 shares worth $70.7M.
  • Avoro Capital Advisors added most to Cytokinetics in Q2 2026, an estimated $120M increase.
  • Avoro Capital Advisors's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $6.93M.
  • Avoro Capital Advisors fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $492M.
  • Avoro Capital Advisors's ten largest holdings make up 79% of its $11.1B portfolio in Q2 2026.
  • Avoro Capital Advisors opened 2 new positions and closed 8 in Q2 2026.
  • Avoro Capital Advisors's portfolio value rose 9.6% quarter-over-quarter to $11.1B.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.